Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
3,670,236
-
Share change
-
-87,250
-
Total reported value
-
$6,016,884
-
Put/Call ratio
-
19%
-
Price per share
-
$1.64
-
Number of holders
-
41
-
Value change
-
-$246,998
-
Number of buys
-
14
-
Number of sells
-
12
Institutional Holders of BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) as of Q4 2022
As of 31 Dec 2022,
BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) was held by
41 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,670,236 shares.
The largest 10 holders included
VANGUARD GROUP INC, BlackRock Inc., ABNER HERRMAN & BROCK LLC, GEODE CAPITAL MANAGEMENT, LLC, RAYMOND JAMES & ASSOCIATES, Ikarian Capital, LLC, PRICE T ROWE ASSOCIATES INC /MD/, SUSQUEHANNA INTERNATIONAL GROUP, LLP, STATE STREET CORP, and Weaver Consulting Group.
This page lists
41
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.